3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Papillomavirus Infections
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
COVID-19
1
Interventions
Rituximab
59
Cyclophosphamide
35
Vincristine
28
Doxorubicin
24
Prednisone
22
Bendamustine Hydrochloride
17
Etoposide
15
Radiotherapy
12
Cytarabine
10
Peripheral Blood Stem Cell Transplantation
8
Filgrastim
8
ibrutinib
7
VAP-cyclo protocol
7
Prednisolone
7
Methotrexate
7
Granulocyte Colony-Stimulating Factor
7
ibritumomab tiuxetan
6
fludarabine
6
Melphalan
6
Gemcitabine
6
pirtobrutinib
5
Mitoxantrone
5
Lenalidomide
5
Carmustine
5
Bleomycin
5
pixantrone
4
Mycophenolic Acid
4
Methylprednisolone
4
Ifosfamide
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Non-Hodgkin
×
2019-nCoV Vaccine mRNA-1273
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled